subscribeSubscribe
Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO

Onco360 Selected as the Preferred National Specialty Pharmacy Partner for XPOVIO
BUSINESSWIRE
13 Mar 2024
Share Share
Antengene Announces Inclusion of XPOVIO in National Reimbursement Drug List

Antengene Announces Inclusion of XPOVIO in National Reimbursement Drug List
PR NEWSWIRE
14 Dec 2023
Share Share
Antengene Announces Inclusion of XPOVIO in 2023 China`s Drug List

Antengene Announces Inclusion of XPOVIO in 2023 China`s Drug List
PR NEWSWIRE
13 Dec 2023
Share Share
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib

Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib
PR NEWSWIRE
10 Dec 2023
Share Share
Karyopharm Announces Clinical Trial Collaboration with BMS to Evaluate CC- 92480

Karyopharm Announces Clinical Trial Collaboration with BMS to Evaluate CC- 92480
PR NEWSWIRE
30 Oct 2023
Share Share
Antengene, Hansoh Pharma enter partnership to commercialize Xpovio

Antengene, Hansoh Pharma enter partnership to commercialize Xpovio
PHARMABIZ
12 Aug 2023
Share Share
Karyopharm cuts staff amid push to broaden use of blood cancer drug

Karyopharm cuts staff amid push to broaden use of blood cancer drug
Delilah Alvarado BIOPHARMADIVE
03 Aug 2023
Share Share
Karyopharm Initiates Pivotal Ph3 Study of XPO1 Inhibitor Selinexor & Ruxolitinib

Karyopharm Initiates Pivotal Ph3 Study of XPO1 Inhibitor Selinexor & Ruxolitinib
PR NEWSWIRE
28 Jun 2023
Share Share
Menarini Group Shares NEXPOVIO Subgroup Data from BOSTON trial

Menarini Group Shares NEXPOVIO Subgroup Data from BOSTON trial
PR NEWSWIRE
08 Jun 2023
Share Share
Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS

Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS
PR NEWSWIRE
31 May 2023
Share Share